Clay Siegall got his a Ph.D in Genetics from George Washington University and also B.S in Zoology from the University of Maryland. He is a well-accomplished businessman and scientist. For over the years he has worked in the biotechnology industry hence attaining a lot of experience. Additionally he was given an award for being among the 2013 Alumnus of the year for computer, Natural sciences and Math from the University of Maryland. Clay Siegall started Seattle Genetic is a company in the year 1998. He is the CEO and the President of the company. He also is the chairman of the board of members at the company
Biotechnology deals with the making of technology in the world of science or it is the usage of many microorganisms to carry out particular engineering procedures in order to provide artificial hormones and drugs. Seattle Genetic end goals to the cancer patients are to provide the best antibody drug conjugates (ADC) and also proper service to patients as a biotechnology company. Clay Siegall and his staffs guarantee that they work hard in order to assist the patients with cancer to attain treatment they need. The company first product was Adcetric which has reached over 60 countries all over the universe.
The economical rate of the company has risen due to Clay Siegall and his team effort through hard work and dedication they keep doing. Through his expertise and experience it has managed to position more than 20 ADCs of the company’s understanding in several clinical developments. The company private and public economic status has approximately attained $330 million in over the years. Patients who have Lymphoma who are more than 15,000 in various countries have been cured with Adcetris.
Seattle Genetic has other products such as SGN-CD19A in non-Hodgkin lymphoma and SGN-CD33A in acute myeloid leukemia that are used in medicals. Clay Siegall is fascinated with the good effects of the cures. He and the corporation they are certain that there will be advanced treating therapies in the future to improve the lives of cancer patients. Clay Siegall and the company have joined together with various other companies to enhance the therapies of cancer treatment.